Search

Displaying results 3491 - 3500 of 5263 in total
  1. Drug

    Anthoxanthum odoratum

    go.drugbank.com/drugs/DB14163
    Approved

    Anthoxanthum odoratum allergenic extract is used in allergenic testing.

  2. Drug

    Cretostimogene grenadenorepvec

    go.drugbank.com/drugs/DB05148
    Investigational

    CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF.

  3. Drug

    INKP-102

    go.drugbank.com/drugs/DB05326
    Experimental

    INKP-102 is the next generation sodium phosphate tablet designed to aid bowl preparation before colonoscopy.

  4. Drug

    2-hydroxy-6-oxo-6-phenyl-2,4-hexadienoic acid

    go.drugbank.com/drugs/DB07914
    Experimental

    Metabolic product of biphenyl; from Pseudomonas putida.

  5. Drug

    V24343

    go.drugbank.com/drugs/DB05201
    Investigational

    The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.

  6. Drug

    Human Embryonic Stem Cell-derived M Cell

    go.drugbank.com/drugs/DB15734
    Investigational

    These IMRCs are differentiated from human embryonic stem cells that are expanded and then harvested.

  7. Drug

    Allosamidin

    go.drugbank.com/drugs/DB04628
    Experimental

    Allosamidin exhibits extremely potent inhibitory activity against chitinases from a number of sources, particularly from <i>Candida albicans</i>, and can be utilized as potent antifungal agent.

  8. Drug

    Taberminogene vadenovec

    go.drugbank.com/drugs/DB05011
    Experimental

    EG004 has completed a Phase II trial, this being the first part of the Phase II/III study for which it has received approval from the US Recombinant DNA Advisory Committee (RAC).

  9. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    . was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc

  10. Drug

    Ulobetasol

    go.drugbank.com/drugs/DB00596
    Approved

    Ulobetasol is a highly potent corticosteroid. It is structurally related to clobetasol. Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses. Ulobetasol was...